This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Emerging Strategies in the Management of Dyslipidemia in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia: PCSK9 Inhibitors (Evolocumab and Alirocumab)

Emerging Strategies in the Management of Dyslipidemia in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia: PCSK9 Inhibitors (Evolocumab and Alirocumab)

Format

Webcast

Time to Complete

1 hour

Released

October 10, 2017

Expires

October 10, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / ANCC Contact Hour
1.00 / CE for Pharmacists (0.10 CEUs)

Accredited Provider

This webcast is jointly provided by MedNet, LLC and Amedco.

Commercial Supporters

Supported by Amgen, Inc.

Program Description

This webcast is intended to improve care of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia, and diabetes by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of primary care physicians, internal medicine, family medicine physicians, endocrinologists, cardiologists, lipidologists, diabetologists, registered nurses, pharmacists and allied healthcare professionals involved in the diagnosis and treatment of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia and diabetes.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Outline risk assessment tools to identify dyslipidemia patients who may benefit from further reduction in low-density lipoprotein-cholesterol (LDL-C)
  • Assess the impact of PCSK9 inhibitors evolocumab and alirocumab on LDL-C and cardiovascular risk in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia, and diabetes

Conflict Of Interest Disclosure Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Faculty

Harold Bays, MD
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center (L-MARC Research Center)
Louisville, KY

Dr. Bays discloses that he is a consultant and advisor of Alnylam, Akeea, Amgen, AstraZeneca, Eisai, Lilly USA, LLC, Esperion, Ionis (ISIS), Janssen, Johnson & Johnson, Kowa, Merck, Novartis, Prosciento, Regeneron and Sanofi, and received research funding from Amarin, Amgen, Alere, Allergan, Arisaph, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis, Cymabay, Dr. Reddy Labs, Eisai, Lilly USA, LLC, Esperion, Ferrer/Chiltern, Gemphire, Gilead, GSK, Janssen, Johnson & Johnson, Kowa, Merck, Necktar, Nichi-iko, Novartis, Novo Nordisk, Orexigen, Pfizer, Pronova, Regeneron, Sanofi, Selecta, Takeda and TIMI, and was on speaker’s bureau of Amarin, Amgen, Eisai, Kowa, Orexigen, Regeneron and Sanofi. Neither Harold E. Bays, MD or his affiliated research center own pharmaceutical stocks or patents.

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Harold Bays listed his disclosures under the Faculty heading above.

Kamatham A. Naidu, PhD (MedNet, LLC), has no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and MedNet, LLC. Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Amedco designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CE for Nurses

Accreditation Statement

Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and MedNet, LLC.

Designation Statement

Maximum of 1.00 contact hour.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This activity provides 1.00 contact hours (0.10 CEUs) - Knowledge based credits ACPE Universal Activity Number: 0453-9999-17-492-H04-P

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

NON-ENDORSEMENT OF PRODUCTS
Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating in or receiving credit for this webcast. During the period October 10, 2017 through October 10, 2018, participants must read all of the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue